A new drug application has been submitted to the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Elevar Therapeutics Names Wade Smith Chief Financial OfficerTwo-decade industry veteran joined Elevar as VP of finance in January - read this article along with other careers information, tips and advice on BioSpace